literature

HBV mutation literature information.

Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.

PMID: 18617782 2008 European journal of gastroenterology & hepatology

Abstract: During entecavir treatment, the rtS202G mutation was selected.

Successful treatment of an entecavir-resistant hepatitis B virus variant.

PMID: 17935165 2007 Journal of medical virology

Abstract: Direct sequence analysis of the ETV-resistant strain showed appearance of amino acid substitution rtS202G in the reverse transcriptase (RT) domain, together with rtL180M + M204V substitution that had developed at the emergence of LAM-resistant mutant.

Abstract: In conclusion, this study showed that virological and biochemical breakthrough due to ETV could occur in patients infected with LAM-resistant HBV and confirmed that the addition of rtS202G substitution to the rtL180M + M204V mutant strain is responsible for ETV resistance and we could treat the resistant

Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.

PMID: 17239478 2007 Journal of hepatology

Abstract: Although the rtL180M+S202G+M204V variant, that prevailed at the end of entecavir therapy, did not show the highest viral genome replication capacity, it conferred one of the strongest resistance levels to entecavir.

Abstract: Three years later, the viral load rose again, and a complex mixture of entecavir-resistant strains, all harboring the lamivudine-resistance signature rtL180M+M204V and the rtS202G mutation were observed.

Entecavir resistance is rare in nucleoside naive patients with hepatitis B.

PMID: 17133475 2006 Hepatology (Baltimore, Md.)

Abstract: Three ETV rebounds were attributable to LVDr virus present at baseline, with one having a S202G ETV resistance (ETVr) substitution emerge at Week 48.

Browser Board

Co-occurred Entities

Filtrator